Norgine Company Profile

Background

Overview

Norgine is a leading European specialist pharmaceutical company with over a century of experience in delivering transformative medicines to patients. Established in 1906, the company has a direct presence in 18 European countries, as well as Australia and New Zealand. In 2023, Norgine reported net product sales exceeding €500 million and provided support to over 25 million patients globally.

Mission and Vision

Norgine's mission is to transform patients' lives by providing innovative and high-quality medicines. The company's vision is to bring transformative products to Europe that add value and benefits to healthcare systems and patients.

Primary Area of Focus

Norgine specializes in therapeutic areas such as gastroenterology, hepatology, oncology, and supportive care. The company is dedicated to addressing significant unmet clinical needs within these fields.

Industry Significance

With over 25 million patients supported annually and a robust portfolio of products, Norgine holds a significant position in the European pharmaceutical industry. Its integrated approach, encompassing manufacturing, development, and commercialization, enables the company to deliver high-quality, transformative medicines effectively.

Key Strategic Focus

Core Objectives

Norgine aims to expand its presence in Europe, Australia, and New Zealand by acquiring, developing, and commercializing specialist and innovative products that make a real difference to patients' lives.

Specific Areas of Specialization

The company focuses on gastroenterology, hepatology, oncology, and supportive care, striving to address significant unmet clinical needs in these therapeutic areas.

Key Technologies Utilized

Norgine employs advanced manufacturing technologies at its facilities in Hengoed, Wales, and Dreux, France, ensuring the production of high-quality medicines.

Primary Markets Targeted

The company targets major European markets, Australia, and New Zealand, with a strong global network of partnerships in non-Norgine markets.

Financials and Funding

Funding History

Norgine is a privately held company and does not publicly disclose detailed funding histories.

Total Funds Raised

Specific details regarding total funds raised are not publicly available.

Recent Funding Rounds

As a privately held entity, Norgine has not publicly disclosed recent funding rounds.

Notable Investors

Information about individual investors is not publicly disclosed.

Intended Utilization of Capital

Norgine utilizes its capital to support the development, manufacturing, and commercialization of its pharmaceutical products, as well as to invest in infrastructure and strategic partnerships.

Pipeline Development

Key Pipeline Candidates

Norgine's pipeline includes products in various stages of development across its therapeutic areas, focusing on addressing unmet clinical needs.

Stages of Clinical Trials or Product Development

The company is involved in research and development activities, with products in various stages of clinical development.

Target Conditions

Norgine targets conditions in gastroenterology, hepatology, oncology, and supportive care.

Relevant Timelines for Anticipated Milestones

Specific timelines for pipeline milestones are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

Norgine has developed proprietary manufacturing processes at its facilities in Hengoed, Wales, and Dreux, France, ensuring the production of high-quality medicines.

Significant Scientific Methods

The company employs advanced manufacturing technologies to produce its pharmaceutical products.

AI-Driven Capabilities

Specific details regarding AI-driven capabilities are not publicly disclosed.

Leadership Team

Peter Stein – Chairman and Chief Executive Officer

Peter Stein is the Chairman and Chief Executive Officer and principal shareholder of the Norgine Group. He also serves as the Chief Executive of Norgine Ventures, which provides financing solutions to innovative healthcare companies.

Janneke van der Kamp – Chief Executive Officer

Janneke van der Kamp became the CEO of Norgine in January 2025.

Leadership Changes

In January 2025, Janneke van der Kamp succeeded Peter Stein as CEO of Norgine.

Competitor Profile

Market Insights and Dynamics

The European pharmaceutical market is characterized by a strong presence of specialist companies focusing on specific therapeutic areas. Norgine competes with other companies in gastroenterology, hepatology, oncology, and supportive care.

Competitor Analysis

Key competitors include:

Octapharma: A global company specializing in human proteins, with a focus on immunotherapy and hematology.

Bausch Health: A multinational company offering a diverse range of pharmaceutical products, including those in gastroenterology and ophthalmology.

Strategic Collaborations and Partnerships

Norgine has entered into several strategic collaborations, including:

AMAG Pharmaceuticals: In July 2020, Norgine entered into an exclusive licensing agreement to commercialize ciraparantag in Europe, Australia, and New Zealand.

Fennec Pharmaceuticals: In March 2024, Norgine secured an exclusive licensing agreement to commercialize PEDMARQSI in Europe, Australia, and New Zealand.

Operational Insights

Norgine's integrated approach, encompassing manufacturing, development, and commercialization, enables the company to deliver high-quality, transformative medicines effectively. The company's strong presence in Europe, Australia, and New Zealand, along with its strategic partnerships, strengthen its market position.

Strategic Opportunities and Future Directions

Strategic Roadmap

Norgine aims to expand its portfolio by acquiring, developing, and commercializing innovative products that address unmet clinical needs in its therapeutic areas.

Future Business Directions

The company plans to enhance its presence in existing markets and explore opportunities in new regions through strategic partnerships and acquisitions.

Opportunities for Expansion

Norgine continues to seek collaborations that align with its strategic focus on gastroenterology, hepatology, oncology, and supportive care.

Positioning for Future Objectives

Norgine's integrated infrastructure, experienced leadership, and commitment to innovation position the company to achieve its future objectives in the pharmaceutical industry.